Managing the ADR of Stevens-Johnson syndrome/toxic epidermal necrolysis

References

• Heng YK, Lee HY, Roujeau JC. Epidermal necrolysis: 60 years of errors and advances. Br J Dermatol. 2015;173(5):1250–1254.
   PubMed Web of Science ®Google Scholar
• Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–96.
   PubMedGoogle Scholar
• Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013;133(5):1197–1204.
   PubMed Web of Science ®Google Scholar
• Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol. 2008;58(1):33–40.
   PubMed Web of Science ®Google Scholar
• Hsu DY, Brieva J, Silverberg NB, et al. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136(7):1387–1397.
   PubMed Web of Science ®Google Scholar
• Chaby G, Maldini C, Haddad C, et al. Incidence of and mortality from epidermal necrolysis (Stevens–Johnson syndrome/toxic epidermal necrolysis) in France during 2003–16: a four‐source capture–recapture estimate. Br J Dermatol. 2020;182(3):618–624.
   PubMed Web of Science ®Google Scholar
• Frey N, Jossi J, Bodmer M, et al. The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol. 2017;137(6):1240–1247.
   PubMed Web of Science ®Google Scholar
• Duong TA, Valeyrie-Allanore L, Wolkenstein P, et al. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390(10106):1996–2011.
   PubMed Web of Science ®Google Scholar
• Bequignon E, Duong TA, Sbidian E, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: ear, nose, and throat description at acute stage and after remission. JAMA Dermatol. 2015;151(3):302–307.
   PubMed Web of Science ®Google Scholar
• Roujeau JC, Robert SS. Severe adverse Cutaneous Reactions to Drugs. N Engl J Med. 1994;133(19):1272–1285.
   Google Scholar
• Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138(8):1019–1024.
   PubMedGoogle Scholar
• Mockenhaupt M, Viboud C, Dunant A, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. the euroSCAR-study. J Invest Dermatol. 2008;128(1):35–44.
   PubMed Web of Science ®Google Scholar
• Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333(24):1600–1607.
   PubMed Web of Science ®Google Scholar
• Wang YH, Chen CB, Tassaneeyakul W, et al. The medication risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in asians: the major drug causality and comparison with the US FDA label. Clin Pharmacol Ther. 2019;105(1):112–120.
   PubMed Web of Science ®Google Scholar
• Sassolas B, Haddad C, Mockenhaupt M, et al., ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clinical Pharmacology & Therapeutics. 2010;88(1):60–68. .
   PubMed Web of Science ®Google Scholar
• Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136(3):323–327.
   PubMedGoogle Scholar
• Liew YCC, Choo KJL, Oh CC, et al. Mycoplasma-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: case-control analysis of a cohort managed in a specialized center. J Am Acad Dermatol. 2021;S0190-9622(21):811–817.
   Google Scholar
• Roujeau JC, Dunant A, Mockenhaupt MEN. Ocular Complications, and “Cold Medicines. J Allergy Clin Immunol Pract. 2018;6(2):703–704.
   PubMed Web of Science ®Google Scholar
• Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123(2):e297–304.
   PubMed Web of Science ®Google Scholar
• Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149–153.
   PubMed Web of Science ®Google Scholar
• Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol. 2006;126(2):272–276.
   PubMed Web of Science ®Google Scholar
• Noe MH, Rosenbach M, Hubbard RA, et al. Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson syndrome/toxic epidermal necrolysis-ABCD-10. JAMA Dermatol. 2019;155(4):448–454.
   PubMed Web of Science ®Google Scholar
• Koh HK, Fook-Chong S, Lee HY. Assessment and comparison of performance of ABCD-10 and SCORTEN in prognostication of epidermal necrolysis. JAMA Dermatol. 2020;156(12):1294–1299.
   PubMed Web of Science ®Google Scholar
• Duplisea MJ, Roberson ML, Chrisco L, et al. Performance of ABCD-10 and SCORTEN mortality prediction models in a cohort of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. J Am Acad Dermatol. 2021;85(4):873–877.
   PubMed Web of Science ®Google Scholar
• Koh HK, Fook-Chong S, and Lee HY. Improvement of mortality prognostication in patients with epidermal necrolysis: the role of novel inflammatory makers and proposed revision of SCORTEN (Re-SCORTEN). JAMA Dermatol. 2022. DOI:10.1001/jamadermatol.2021.5119
   PubMed Web of Science ®Google Scholar
• Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in u.s. burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002;23(2):87–96.
   PubMedGoogle Scholar
• Clark AE, Fook-Chong S, Choo K, et al. Delayed admission to a specialist referral center for Stevens-Johnson syndrome and toxic epidermal necrolysis is associated with increased mortality: a retrospective cohort study. JAAD International. 2021; 4: 10–12. 10.1016/j.jdin.2021.03.008
   PubMedGoogle Scholar
• Traikia C, Hua C, Le Cleach L, et al. Individual‐ and hospital‐level factors associated with epidermal necrolysis mortality: a nationwide multilevel study, France, 2012–2016. Br J Dermatol. 2020;182(4):900–906.
   PubMed Web of Science ®Google Scholar
• Creamer D, Walsh SA, Dziewulski P, et al. U.K. guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174(6):1194–1227.
   PubMed Web of Science ®Google Scholar
• Shiga S, Cartotto R. What are the fluid requirements in toxic epidermal necrolysis? J Burn Care Res. 2010;31(1):100–104.
   PubMed Web of Science ®Google Scholar
• Seminario-Vidal L, Kroshinsky D, Malachowski SJ, et al. Society of dermatology hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. J Am Acad Dermatol. 2020;82(6):1553–1567.
   PubMed Web of Science ®Google Scholar
• Graves C, Faraklas I, Maniatis K, et al. Nutrition in toxic epidermal necrolysis: a multicenter review. Nutr Clin Pract. 2016;31(6):836–840.
   PubMed Web of Science ®Google Scholar
• Clayton NA, Kennedy PJ. Management of dysphagia in toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS). Dysphagia. 2007;22(3):187–192.
   PubMed Web of Science ®Google Scholar
• Gendreau S, Amiot A, Le Baleur Y, et al. Gastrointestinal involvement in Stevesn-Johnson syndrome and toxic epidermal necrolysis: a retrospective case series. Br J Dermatol. 2019;182(1):180–1234–5.
   Google Scholar
• Singer P, Blaser AR, Berger MM, et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr. 2019;38(1):48–79.
   PubMed Web of Science ®Google Scholar
• Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987;123(9):1160–1165.
   PubMedGoogle Scholar
• Koh HK, Chai ZT, Tay HW, et al. Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: a cohort study of 176 patients. J Am Acad Dermatol. 2019;81(3):686–693.
   PubMed Web of Science ®Google Scholar
• de Prost N, Ingen-Housz-Oro S, T Anh D, et al. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore). 2010;89(1):28–36.
   PubMed Web of Science ®Google Scholar
• Lecadet A, Woerther PL, Hua C, et al. Incidence of bloodstream infections and predictive value of qualitative and quantitative skin cultures of patients with overlap syndrome or toxic epidermal necrolysis: a retrospective observational cohort study of 98 cases. J Am Acad Dermatol. 2019;81(2):342–347.
   PubMed Web of Science ®Google Scholar
• Wang Q, Tian XB, Liu W, et al. Procalcitonin as a diagnostic indicator for systemic bacterial infections in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. J Dermatol. 2018;45(8):989–993.
   PubMed Web of Science ®Google Scholar
• Lee HY. Wound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: an unmet need. J Am Acad Dermatol. 2018;79(4):e87–e88.
   PubMed Web of Science ®Google Scholar
• Dorafshar AH, Dickie SR, Cohn AB, et al. Antishear therapy for toxic epidermal necrolysis: an alternative treatment approach. Plast Reconstr Surg. 2008;122(1):154–160.
   PubMed Web of Science ®Google Scholar
• Haravu PN, Gottlieb LJ, Vrouwe SQ. Antishear therapy for Stevens-Johnson Syndrome and toxic epidermal necrolysis: a follow-up study. J Burn Care Res. 2021;155. DOI:10.1093/jbcr/irab155
   Web of Science ®Google Scholar
• Castillo B, Vera N, Ortega-Loayza A, et al. Wound care for Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol. 2018;79(4):764–767.
   PubMed Web of Science ®Google Scholar
• Gueudry J, Roujeau J-C, Binaghi M, et al. Risk Factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol. 2009;145(2):6.
   Google Scholar
• Kohanim S, Palioura S, Saeed HN, et al. Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis – a comprehensive review and guide to therapy. II. ophthalmic disease. Ocul Surf. 2016;14(2):168–188.
   PubMed Web of Science ®Google Scholar
• Lee HY, Walsh SA, Creamer D. Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up. Br J Dermatol. 2017;177(4):924–935.
   PubMed Web of Science ®Google Scholar
• Mieno H, m U, Kinoshita F, et al. Corticosteroid pulse therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis patients with acute ocular involvement. Am J Ophthalmol. 2021;231:194–199.
   PubMed Web of Science ®Google Scholar
• Shammas MC, Lai EC, Sarkar JS, et al. Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids. Am J Ophthalmol. 2010;149(2):203.
   PubMed Web of Science ®Google Scholar
• Sharma N, Thenarasun SA, Kaur M, et al. Adjuvant role of amniotic membrane transplantation in acute ocular Stevens-Johnson syndrome: a randomized control trial. Opthalmology. 2016;123(3):484.
   PubMed Web of Science ®Google Scholar
• Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med. 1997;23(12):1237–1244.
   PubMed Web of Science ®Google Scholar
• Beck A, Cooney R, Gamelli RL, et al. Predicting mechanical ventilation and mortality: early and late indicators in Steven–Johnson syndrome and toxic epidermal necrolysis. J Burn Care Res. 2016;37(1):e47–e55.
   PubMed Web of Science ®Google Scholar
• de Prost N, Mekontso-Dessap A, Valeyrie-Allanore L, et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation*. Crit Care Med. 2014;42(1):118–128.
   PubMed Web of Science ®Google Scholar
• Ingen-Housz-Oro S, Duong T-A, Bensaid B, et al. Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins). Orphanet J Rare Dis. 2018;13(1):56.
   PubMedGoogle Scholar
• Wolkenstein P, Latarjet J, Roujeau J-C, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998;352(9140):1586–1589.
   PubMed Web of Science ®Google Scholar
• Wang C-W, Yang L-Y, Chen C-B, et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128(3):985–996.
   PubMed Web of Science ®Google Scholar
• Zimmermann S, Sekula P, Venhoff M, et al. Systemic immunomodulating therapies for Stevens-Johnson Syndrome and Toxic Epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2017;153(6):514–522.
   PubMed Web of Science ®Google Scholar
• Torres-Navarro I, de Unamuno-Bustos B, Botella-Estrada R. Systematic review of BRAF/MEK inhibitors-induced severe cutaneous adverse reactions (SCARs). J Eur Acad Dermatol Venereol. 2021;35(3):607–614.
   PubMed Web of Science ®Google Scholar
• Tsai TY, Huang IH, Chao YC, et al. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis. J Am Acad Dermatol. 2021;84(2):390–397.
   PubMed Web of Science ®Google Scholar
• Lian SB, Oh CC, Yeo YW, et al. Spectrum of nail sequelae in Stevens-Johnson syndrome and toxic epidermal necrolysis. JAMA Dermatol. 2021;157(1):117–119.
   PubMed Web of Science ®Google Scholar
• Hoffman M, Chansky PB, Bashyam AR, et al. Long-term physical and psychological outcomes of Stevens-Johnson syndrome/toxic epidermal necrolysis. JAMA Dermatol. 2021;157(6):712–715.
   PubMed Web of Science ®Google Scholar
• Ingen‐Housz‐Oro S, Alves A, Colin A, et al. Health‐related quality of life and long‐term sequelae in survivors of epidermal necrolysis: an observational study of 57 patients. Br J Dermatol. 2020;182(4):916–926.
   PubMed Web of Science ®Google Scholar
• Dodiuk-Gad RP, Olteanu C, Feinstein A, et al. Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2016;175(2):422–424.
   PubMed Web of Science ®Google Scholar
• Lefaucheur JP, Valeyrie‐Allanore L, Ng Wing Tin S, et al. Chronic pain: a long‐term sequela of epidermal necrolysis (Stevens–Johnson syndrome/toxic epidermal necrolysis) – prevalence, clinical characteristics and risk factors. J Eur Acad Dermatol Venereol. 2021;35(1):188–194.
   PubMed Web of Science ®Google Scholar
• Chaby G, Valeyrie-Allanore L, Duong TA, et al. Severe cutaneous adverse reactions due to inappropriate medication use. Br J Dermatol. 2018;179(2):329–336.
   PubMed Web of Science ®Google Scholar
• Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome/toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58(1):25–32.
   PubMed Web of Science ®Google Scholar
• Lee HY, Pang SM, Thamotharampillai T. Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol. 2008;59(2):352–353.
   PubMed Web of Science ®Google Scholar
• Chung W-H, Hung S-I, Hong H-S, et al. A marker for Stevens–Johnson syndrome. Nature. 2004;428(6982):486.
   PubMed Web of Science ®Google Scholar
• Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 Screening in Taiwan. N Engl J Med. 2011;364(12):1126–1133.
   PubMed Web of Science ®Google Scholar
• Ko TM, Tsai CY, Chen SY, et al. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ. 2015;351:h4848.
   PubMedGoogle Scholar
• Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics. 2012;13(11):1285–1306.
   PubMed Web of Science ®Google Scholar
• Toh DSL, Tan LL, Dcw A, et al. Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study. Pharmacogenomics J. 2014;14(4):316–321.
   PubMed Web of Science ®Google Scholar
• Tan-Koi WC, Sung C, Chong YY, et al. Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach. Pharmacogenomics. 2017;18(9):881–890.
   PubMed Web of Science ®Google Scholar
• Hsu DY, Brieva J, Silverberg N, et al. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol. 2017;76(5):811–817.
   PubMed Web of Science ®Google Scholar
• Finkelstein Y, Soon GS, Acuna P, et al. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011;4(4):723–728.
   Google Scholar
• Antoon JW, Goldman JL, Shah S, et al. A retrospective cohort study of the management and outcomes of children hospitalized with Stevens-Johnson syndrome or toxic epidermal necrolysis. J Allergy Clin Immunol Pract. 2019;7(1):244–250.
   PubMed Web of Science ®Google Scholar
• Wu J, Lee YY, Su SC, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignancies. Br J Dermatol. 2015;173(5):1224–1231.
   PubMed Web of Science ®Google Scholar
• Goldinger SM, Stieger P, Meier B, et al. Cytotoxic cutaneous adverse drug reactions during anti-PD1 therapy. Clin Cancer Res. 2016;22(16):4023–4029.
   PubMed Web of Science ®Google Scholar
• Zhu J, Chen G, He Z, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database. E ClinicalMedicine. 2021; 37: 100951. 10.1016/j.eclinm.2021.100951
   PubMedGoogle Scholar
• Maloney N, Ravi V, Cheng K, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis like reactions to checkpoint inhibitors: a systematic review. Int J Dermatol. 2020;59(6):E183–8.
   PubMed Web of Science ®Google Scholar
• Besari AM, Lim JA, Vellaichamy PT, et al. Stevens Johnson syndrome as a primary manifestation of COVID-19. Postgrad Med J. 2021.
   Web of Science ®Google Scholar
• Dash S, Sirka CS, Mishra S, et al. COVID-19 vaccine induced Stevens-Johnson syndrome: a case report. Clin Exp Dermatol. 2022. DOI:10.1111/CED.14784
   Web of Science ®Google Scholar
• Bulat V, Likic R, Pondeljak N, et al. Pholcodine-induced Stevens-Johnson syndrome in a patient with COVID-19. Postgrad Med J. 2021:1–2. Epub ahead of print: 20 Apr 2021. DOI:10.1136/postgradmedj-2021-139892.
   PubMed Web of Science ®Google Scholar
• Kong J, Cuevas-Castillo F, Nassar, et al. Bullous drug eruption after second dose of mRNA-1273 (Moderna COVID-19 vaccine: case report. J Infect Pub Health. 2021;14(10):1392–1394.
   PubMed Web of Science ®Google Scholar
• Bakir M, Almeshal H, Alturji R, et al. Toxic epidermal necrolysis post COVID-19 vaccination – first reported case. Cureus. 2021;13(8):e17215.
   PubMed Web of Science ®Google Scholar
• Mansouri P, Chalanagari R, Martits-Chalangari K, et al. Stevens-Johnson syndrome due to COVID 19 vaccination. Clin Case Rep. 2021;9(e05099). DOI:10.1002/ccr3.5099
   Google Scholar